TRACON Pharmaceuticals Announces Clinical Data Presentation At Upcoming Connective Tissue Oncology Society (CTOS) 2016 Annual Meeting

SAN DIEGO, Nov. 03, 2016 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases, today announced the following presentation at the upcoming Connective Tissue Oncology Society (CTOS) 2016 Annual Meeting in Lisbon, Portugal:
Title: TRC105 (Endoglin Antibody) in Combination with Pazopanib in Patients with Advanced Angiosarcoma
Session Title:  Poster Session 2 - Soft Tissue Sarcomas - Poster 110  
Presenter: K. Kumar Sankhala, M.D., Sarcoma Oncology Research Center, Santa Monica, CA  
Location: Corinthia Hotel Lisbon, Lisbon, Portugal  
Date/Time: Friday, November 11, 2016, 10:40 AM - 7:00 PM, Western Europe Time  

About TRC105 (carotuximab)

TRC105 (carotuximab) is a novel, clinical stage antibody to endoglin, a protein overexpressed on proliferating endothelial cells that is essential for angiogenesis, the process of new blood vessel formation. TRC105 is currently being studied in multiple Phase 2 clinical trials sponsored by TRACON or the National Cancer Institute for the treatment of solid tumor types in combination with VEGF inhibitors. The ophthalmic formulation of TRC105, DE-122, is currently in a Phase 1/2 trial for patients with wet AMD. TRC205, a second generation antibody to endoglin, is undergoing preclinical testing in models of fibrosis. For more information about the clinical trials, please visit TRACON's website at

If you liked this article you might like

6 Stocks Spiking on Big Volume

IPO Roundup: Shake Shack Shares More Than Double Out of Gate